CN103079544B - 包含丁丙诺啡的可注射的可流动组合物 - Google Patents

包含丁丙诺啡的可注射的可流动组合物 Download PDF

Info

Publication number
CN103079544B
CN103079544B CN201180039223.3A CN201180039223A CN103079544B CN 103079544 B CN103079544 B CN 103079544B CN 201180039223 A CN201180039223 A CN 201180039223A CN 103079544 B CN103079544 B CN 103079544B
Authority
CN
China
Prior art keywords
buprenorphine
implant
pharmaceutical composition
flowable
metabolites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180039223.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103079544A (zh
Inventor
R·L·诺顿
A·瓦特金斯
周明兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rb Pharmaceutical Co ltd
Indivior UK Ltd
Original Assignee
Rb Pharmaceutical Co ltd
Indivior UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103079544(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rb Pharmaceutical Co ltd, Indivior UK Ltd filed Critical Rb Pharmaceutical Co ltd
Publication of CN103079544A publication Critical patent/CN103079544A/zh
Application granted granted Critical
Publication of CN103079544B publication Critical patent/CN103079544B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201180039223.3A 2010-06-08 2011-06-06 包含丁丙诺啡的可注射的可流动组合物 Expired - Fee Related CN103079544B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1009549.5 2010-06-08
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
PCT/GB2011/051057 WO2011154724A2 (en) 2010-06-08 2011-06-06 Compositions

Publications (2)

Publication Number Publication Date
CN103079544A CN103079544A (zh) 2013-05-01
CN103079544B true CN103079544B (zh) 2017-06-09

Family

ID=42471306

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180039223.3A Expired - Fee Related CN103079544B (zh) 2010-06-08 2011-06-06 包含丁丙诺啡的可注射的可流动组合物

Country Status (32)

Country Link
US (1) US8921387B2 (enExample)
EP (3) EP3360538B1 (enExample)
JP (2) JP5986072B2 (enExample)
KR (1) KR101865689B1 (enExample)
CN (1) CN103079544B (enExample)
AU (1) AU2011263478B2 (enExample)
BR (1) BR112012031290A2 (enExample)
CA (1) CA2801676C (enExample)
CL (1) CL2012003462A1 (enExample)
CO (1) CO6670529A2 (enExample)
CY (1) CY1120761T1 (enExample)
DK (2) DK3360538T3 (enExample)
ES (2) ES2939612T3 (enExample)
FI (1) FI3360538T3 (enExample)
GB (2) GB2513267B (enExample)
HR (1) HRP20180118T1 (enExample)
HU (1) HUE038275T2 (enExample)
IL (2) IL223488A (enExample)
LT (1) LT2579874T (enExample)
MX (1) MX339209B (enExample)
MY (1) MY171625A (enExample)
NO (1) NO2579874T3 (enExample)
NZ (1) NZ604026A (enExample)
PL (1) PL2579874T3 (enExample)
PT (1) PT2579874T (enExample)
RS (1) RS56820B1 (enExample)
RU (1) RU2607498C2 (enExample)
SG (1) SG186200A1 (enExample)
SI (1) SI2579874T1 (enExample)
SM (1) SMT201800038T1 (enExample)
WO (1) WO2011154724A2 (enExample)
ZA (1) ZA201209233B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
WO2013126552A1 (en) * 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
IN2014DN09238A (enExample) 2012-04-17 2015-07-10 Purdue Pharma Lp
MX387722B (es) * 2012-07-26 2025-03-18 Camurus Ab Formulaciones de opioides.
AU2013294915C1 (en) * 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
EP2931253A1 (en) * 2012-12-13 2015-10-21 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
MX352907B (es) * 2013-03-15 2017-12-13 Heron Therapeutics Inc Composiciones de un poliortoéster y un solvente aprótico.
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US11083730B2 (en) 2014-04-21 2021-08-10 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
BR112016024665B1 (pt) 2014-04-21 2023-04-11 Heron Therapeutics, Inc Composição, composição semissólida e seu uso
EP3134070B1 (en) * 2014-04-21 2020-09-23 Heron Therapeutics, Inc. Compositions of a polyorthoester and an organic acid excipient
PT3137081T (pt) 2014-04-28 2018-02-08 Orphomed Inc Dímero de buprenorfina e o seu uso no tratamento de transtornos gastrointestinais
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
CA2965895C (en) * 2014-11-07 2019-08-06 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
ES2836805T3 (es) * 2015-08-03 2021-06-28 Tolmar International Ltd Sistema de administración de polímeros líquidos para la administración extendida de fármacos
FI3377041T3 (fi) 2015-11-16 2023-11-30 Medincell S A Menetelmä farmaseuttisesti aktiivisten pääainesosien morselloimiseksi ja/tai kohdentamiseksi synoviaalikudokseen
LT3512518T (lt) 2016-09-13 2023-02-10 Alar Pharmaceuticals Inc. Sulėtinto atpalaidavimo buprenorfino vaisto formos
AU2018283724B2 (en) 2017-06-16 2021-08-19 Indivior Uk Limited Methods to treat opioid use disorder
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CA3089114A1 (en) 2018-01-22 2019-07-25 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
AU2019266795B2 (en) 2018-05-11 2023-02-09 Alar Pharmaceuticals Inc. Long-acting injectable formulations and crystalline forms of buprenorphine derivatives
US20210393618A1 (en) 2018-10-11 2021-12-23 Indivior Uk Limited Buprenorphine to treat respiratory depression
US12403291B2 (en) * 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
CN118831057A (zh) * 2023-04-25 2024-10-25 深圳善康医药科技股份有限公司 丁丙诺啡植入剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043432A2 (en) * 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
WO2009091737A2 (en) * 2008-01-14 2009-07-23 Dunn Research & Consulting, Llc Low viscosity liquid polymeric delivery system

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
DK1125577T3 (da) 1994-04-08 2006-06-19 Qlt Usa Inc Væskeformige medikamentindföringspræparater
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
CA2487577C (en) * 2002-05-31 2014-11-18 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
EP1622540A4 (en) * 2003-03-11 2009-12-30 Qlt Usa Inc PREPARATIONS OF ANTI-CANCER AGENTS DEPENDENT ON THE CELLULAR PROGRAM
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
DK1824460T3 (en) * 2004-11-10 2015-01-19 Tolmar Therapeutics Inc Stabilized polymeric delivery system
PL3660073T3 (pl) 2007-02-15 2023-12-27 Tolmar International Limited Poli(laktyd-ko-glikolid) o niskim nagłym uwalnianiu
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043432A2 (en) * 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
WO2009091737A2 (en) * 2008-01-14 2009-07-23 Dunn Research & Consulting, Llc Low viscosity liquid polymeric delivery system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
In Vitro Dissolution Method for Evaluation of Buprenorphine In Situ Gel Formulation: A Technical Note;Richard A. Graves et al.;《AAPS PharmSciTech》;20070803;第8卷(第3期);E1-E4页 *

Also Published As

Publication number Publication date
JP5986072B2 (ja) 2016-09-06
SG186200A1 (en) 2013-01-30
MY171625A (en) 2019-10-21
GB2481018B (en) 2015-03-18
CA2801676A1 (en) 2011-12-15
RU2607498C2 (ru) 2017-01-10
MX2012014335A (es) 2013-03-05
GB201009549D0 (en) 2010-07-21
HRP20180118T1 (hr) 2018-03-09
PT2579874T (pt) 2018-01-29
DK3360538T3 (da) 2023-03-06
EP3360538B1 (en) 2023-02-15
GB201413064D0 (en) 2014-09-03
IL254417A0 (en) 2017-11-30
ES2939612T3 (es) 2023-04-25
AU2011263478A1 (en) 2013-01-10
CL2012003462A1 (es) 2013-04-01
CN103079544A (zh) 2013-05-01
NO2579874T3 (enExample) 2018-06-09
EP4218720A1 (en) 2023-08-02
SI2579874T1 (en) 2018-03-30
RS56820B1 (sr) 2018-04-30
US20130210853A1 (en) 2013-08-15
CO6670529A2 (es) 2013-05-15
ZA201209233B (en) 2014-04-30
MX339209B (es) 2016-04-15
FI3360538T3 (fi) 2023-03-22
ES2656938T3 (es) 2018-03-01
GB2513267B (en) 2015-03-18
PL2579874T3 (pl) 2018-05-30
CA2801676C (en) 2018-08-07
WO2011154724A2 (en) 2011-12-15
JP2016155865A (ja) 2016-09-01
HUE038275T2 (hu) 2018-10-29
SMT201800038T1 (it) 2018-03-08
JP6251774B2 (ja) 2017-12-20
EP3360538A1 (en) 2018-08-15
WO2011154724A9 (en) 2012-08-16
DK2579874T3 (da) 2018-01-29
IL223488A (en) 2017-10-31
AU2011263478B2 (en) 2015-01-22
KR101865689B1 (ko) 2018-06-08
WO2011154724A3 (en) 2012-07-12
EP2579874A2 (en) 2013-04-17
GB2513267A (en) 2014-10-22
RU2012157244A (ru) 2014-07-20
GB2481018A (en) 2011-12-14
JP2013533230A (ja) 2013-08-22
LT2579874T (lt) 2018-02-12
BR112012031290A2 (pt) 2016-11-01
EP2579874B1 (en) 2018-01-10
CY1120761T1 (el) 2019-12-11
US8921387B2 (en) 2014-12-30
KR20130135026A (ko) 2013-12-10
NZ604026A (en) 2015-01-30

Similar Documents

Publication Publication Date Title
CN103079544B (zh) 包含丁丙诺啡的可注射的可流动组合物
US10592168B1 (en) Injectable flowable composition comprising buprenorphine
US8975270B2 (en) Injectable flowable composition comprising buprenorphine
CA2687979C (en) Sustained delivery formulations of risperidone compounds
HK40097172A (en) Injectable flowable composition comprising buprenorphine
HK1184056B (en) Injectable flowable composition comprising buprenorphine
HK1184056A (en) Injectable flowable composition comprising buprenorphine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1184056

Country of ref document: HK

CB02 Change of applicant information

Address after: Burke County, England

Applicant after: The British Virgin UK Ltd

Address before: Burke County, England

Applicant before: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

COR Change of bibliographic data
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1184056

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170609

Termination date: 20190606

CF01 Termination of patent right due to non-payment of annual fee